Recorded: Tuesday 26th October 2021
Session two in the Meet the Expert series will focus on practical management when treatment for CML fails and examination of the novel therapeutic options that are available for patients at this time.
IRCCS/SIRHHC Scientific Institute for Research, Meldola, Italy
Dr. Gianantonio Rosti is a Senior Scientist at the IRCCS/SIRHHC Scientific Institute for Research, Hospitalization and Health Care “Dino Amadori” – Meldola (FC), Italy. He studied Medicine and Surgery at the University of Bologna and was a Fellow at the John Hopkins University Hospital (Baltimore, USA).
Dr. Rosti is a scientific board member of the Italian Group for Adult Hematologic Malignancies Chronic Myeloid Leukemia Working Party [GIMEMA CML WP]), European Investigators on CML (EICML) and a member of the steering committee for the European Treatment and Outcome Study (EUTOS) registry. He is also a member of the ELN recommendation panel (2013 and 2020), the International CML Foundation, and of the scientific board of the Max Foundation. His activitie extends to the no-profit association AIL (Italian Association Against Leukemia), being board member of the Bologna’s regional headquarter in addition to being an author or co-author to more than 300 papers and meetings abstracts.
S.Orsola-Malpighi University Hospital, Bologna, Italy
Prof. Fausto Castagnetti is Professor of Haematology at the University of Bologna (Italy) and Head of the Clinical Research Group on Chronic Myeloid Leukaemia at S. Orsola-Malpighi University Hospital, Bologna. Prof. Castagnetti is also a member of the GIMEMA (Gruppo Italiano Malattie EMatologiche dell’Adulto) CML Working Party (WP) and “European Investigators on CML” Group, and is the Scientific Secretary of the National Board of the GIMEMA CML WP. He has been involved in the EUTOS Project, within the frame of the European LeukemiaNet.
Prof. Castagnetti has been an author or co-author of more than 130 scientific papers, 6 book chapters, more than 350 meeting abstracts. He is the principal investigator or co-investigator in several investigator-initiated and company-sponsored clinical trials, and he has active involvement in grant research projects.
The content and faculty for this program have been independently developed and/or selected by Springer Healthcare. Novartis Pharmaceutical Corporation provided unconditional funding and as such had no involvement with, or influence on the content and selection of faculty. The content is not intended for use by healthcare professionals in the US. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Opinions expressed do not reflect the views of Springer Healthcare. Springer Healthcare assumes no responsibility for any injury or damage to persons or property arising out of, or related to, any use of the material or to any errors or omissions. Please consult the latest prescribing information from the manufacturer for any products mentioned in this material.
Please wait while you are redirected to the right page...
Please share your location to continue.
Check our help guide for more info.